Gabriel M Gutierrez

USPTO Granted Patents = 15 (Patent Applications = 6)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Kensington, MD (US) (2018)
Reston, VA (US) (2016 - 2024)

Company Filing History:

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

1 out of 915

The University of New Mexico

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12370258 - PD-1 and CTLA-4 dual inhibitor peptides (2025-07-29),

2. 12269880 - LAG3 binding peptides (2025-04-08),

3. 11987646 - Immunomodulatory peptides (2024-05-21),

4. 11793856 - PD-1 peptide inhibitors (2023-10-24),

5. 11578102 - LAG3 binding peptides (2023-02-14),

6. 11407829 - LAG3 binding peptides (2022-08-09),

7. 11338040 - Immunomodulatory compounds (2022-05-24),

8. 11033622 - PD-1 and CTLA-4 dual inhibitor peptides (2021-06-15),

9. 10799581 - PD-1 peptide inhibitors (2020-10-13),

10. 10799555 - PD-1 peptide inhibitors (2020-10-13),

11. 10501534 - Anti-malarial compositions (2019-12-10),

12. 10160802 - Anti-malarial compositions (2018-12-25),

13. 10098950 - PD-1 Peptide Inhibitors (2018-10-16),

14. 9943580 - Malaria vaccine (2018-04-17),

15. 9321834 - Anti-malarial compositions (2016-04-26),

Title: Innovator Gabriel M. Gutierrez: Pioneering Therapeutic Peptides

Introduction

Gabriel M. Gutierrez, an innovative inventor based in Reston, Virginia, holds a remarkable portfolio of 14 patents. His groundbreaking work in the field of biomedical research emphasizes the development of therapeutic peptides aimed at addressing critical health challenges. His inventions stand at the intersection of technology and medicine, pushing the boundaries of what's possible in therapeutic applications.

Latest Patents

Gutierrez's recent patents include significant disclosures such as LAG3 binding peptides. This innovation comprises nucleic acids that encode peptides which bind to LAG3, effectively blocking its interaction with molecules such as MHC-II, FGL1, and α-synuclein. These peptides have potential therapeutic applications, including inhibiting the progression of hyperproliferative disorders, such as cancer, and enhancing responses to vaccines.

Another notable patent by Gutierrez pertains to immunomodulatory peptides, which can be employed to treat various conditions, including infectious diseases and sepsis, as well as to promote hair re-pigmentation and lightening of pigmented skin lesions. His contributions are crucial in the ongoing fight against diseases that significantly impact human health.

Career Highlights

Throughout his career, Gutierrez has been associated with leading organizations, including Leidos, Inc. and the United States Department of Health and Human Services. His tenure at these institutions has allowed him to collaborate on transformative projects that have left a lasting impact in the field of biomedical research.

Collaborations

In his journey as an inventor, Gutierrez has collaborated with esteemed colleagues, including James Pannucci and Vinayaka Kotraiah. Their combined expertise has further enriched the quality and applicability of the innovations put forth by Gutierrez, illustrating the collaborative nature of research and invention in tackling complex medical challenges.

Conclusion

Gabriel M. Gutierrez stands out as a dedicated inventor whose work in therapeutic peptides holds promise for the future of medicine. With a robust portfolio of patents and significant collaborations, his contributions are essential in shaping new treatment paradigms for various health issues. The innovations brought forth by Gutierrez signify a bright future in therapeutics, driven by the ever-evolving landscape of medical science.

This text is generated by artificial intelligence and may not be accurate.